Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 18;41(19):3486–3492. doi: 10.1200/JCO.22.01792

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG 1. — Efficacy analyses showing (A) Kaplan-Meier estimate of OS in the overall population, (B) forest plot of OS subgroup analysis, and (C) Kaplan-Meier estimate of investigator-assessed PFS in the overall population. (B) Unless otherwise stated, all analyses are unstratified, and analyses in subgroups with unreported or unknown creatinine clearance or 1L chemotherapy regimen are not shown because of the small number of patients in these subgroups. ^aHRs and CIs were calculated using a Cox proportional hazards model. ^bStratified by best response to 1L chemotherapy (CR or PR v SD) and metastatic disease site when initiating 1L chemotherapy (visceral v nonvisceral). ^cPatients who switched platinum regimens while receiving 1L chemotherapy. 1L, first-line; BSC, best supportive care; CR, complete response; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; PR, partial response; SD, stable disease.